openRxiv
Cure8 research brief
Why This Matters
The study links patient-specific non-coding genetic variation to epithelial regulatory networks and to differences in disease severity and response in a large UC trial, suggesting genetics could help explain why some people respond better to etrolizumab than others.
Who Should Pay Attention
Researchers studying IBD genetics or biomarkers; clinicians and trialists designing precision-medicine approaches or stratified IBD trials; patients and caregivers interested in the science behind treatment response variability.
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract
What To Know
This preprint uses a systems-genomics pipeline (iSNP) to map non-coding SNP effects onto epithelial transcription-factor networks in 452 participants from the etrolizumab phase 3 HICKORY trial and clusters patients by TF activity, relating clusters to disease severity and etrolizumab outcomes.
The key finding reported is that 14 SNP-propagated transcription factors showed differential epithelial regulatory activity and that iSNP-based clustering modestly improved prediction of endoscopic healing (reported p = 0.03) with trends for other clinical and histologic outcomes.
The authors propose this approach could support genetics-informed precision medicine and clinical-trial design in IBD. This summary is based on the article abstract provided by the preprint (structured content depth: abstract). Cure8 has not reviewed the full peer-reviewed paper; treat findings as preliminary until peer review and replication.
Do not interpret this as clinical advice; it is a research finding about genetic and regulatory heterogeneity and its association with trial outcomes.
Keep In Mind
This is a bioRxiv preprint (posted-content) and reflects an abstract-level summary; the work has not completed peer review. Reported associations—including improved prediction of endoscopic healing—should be seen as preliminary and require independent validation.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationopenRxiv
AuthorsYufan Liu, John P. Thomas, Balazs Bohar +4 more
Study typePosted Content
Indexed viaCrossref
Source typeResearch paper
PublishedAug 4, 2026, 12:00 AM
Content availableJournal abstract
Funding disclosed by the source: Wellcome Trust, award 225875/Z/22/Z; Wellcome Trust, award WT101159; Medical Research Council; Biotechnology and Biological Sciences Research Council, award BB/X011054/1; Biotechnology and Biological Sciences Research Council, award BBS/E/F/000PR13631
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Polygenic Risk Scores Show Distinct Genetic Architectures of IBD-Associated Comorbidities.
Shows which IBD comorbidities may be driven in part by shared inherited genetic risk and which likely reflect non-genetic factors, information that could shape future risk stratification and screening approaches for...
Harmonized metagenomic signatures of the gut microbiome reveal robust species, functions, and strain links to inflammatory bowel disease.
The study synthesizes many stool metagenomes to find consistent microbial species, functional pathways, and strain-level differences linked to IBD and to distinctions between Crohn’s disease and ulcerative...
Spatial genetic mapping links shared inflammatory bowel disease liability to adult immune-epithelial lesion contexts.
Links between IBD genetic risk and specific adult tissue lesion contexts help researchers understand which cell types and tissue programs may mediate inherited susceptibility. That can guide future biomarker and...